Frontier Biotechnologies Inc. (SHA:688221)
China · Delayed Price · Currency is CNY 21.62
-2.78 (-11.39%)
At close: Feb 2, 2026
Frontier Biotechnologies Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 137.49 | 125.76 | 110.42 | 83.4 | 40.47 | 46.37 |
Other Revenue | 3.71 | 3.71 | 3.83 | 1.34 | 0.03 | 0.25 |
| 141.2 | 129.47 | 114.25 | 84.74 | 40.5 | 46.62 | |
Revenue Growth (YoY) | 5.63% | 13.33% | 34.82% | 109.22% | -13.13% | 123.50% |
Cost of Revenue | 102.03 | 95.63 | 81.13 | 69.35 | 49.71 | 42.5 |
Gross Profit | 39.17 | 33.84 | 33.12 | 15.39 | -9.21 | 4.12 |
Selling, General & Admin | 180.61 | 171.16 | 159.52 | 135.04 | 136.81 | 109.4 |
Research & Development | 111.73 | 137.21 | 214.23 | 274.33 | 172.11 | 138.49 |
Other Operating Expenses | 20.08 | 4.6 | 3.17 | 2.98 | 1.98 | 1.48 |
Operating Expenses | 311.55 | 310.75 | 377.34 | 413.94 | 312.12 | 249.77 |
Operating Income | -272.37 | -276.9 | -344.22 | -398.56 | -321.33 | -245.65 |
Interest Expense | -9.26 | -10.36 | -8.47 | -4.75 | -1.53 | -1.36 |
Interest & Investment Income | 83.19 | 88.21 | 23.51 | 25.9 | 44.3 | 7.37 |
Currency Exchange Gain (Loss) | 0.15 | 0.15 | -3.58 | 0.68 | 0.09 | -0.62 |
Other Non Operating Income (Expenses) | -1.71 | -3.05 | -0.91 | -2.03 | -0.48 | -0.55 |
EBT Excluding Unusual Items | -200 | -201.95 | -333.66 | -378.75 | -278.96 | -240.81 |
Gain (Loss) on Sale of Investments | -7.41 | 0.08 | -1.06 | -0.25 | 0.72 | 1.27 |
Gain (Loss) on Sale of Assets | -0.08 | -0.03 | -3.08 | -0.01 | 0 | -0 |
Asset Writedown | 2.92 | -36.65 | -3.22 | - | - | - |
Other Unusual Items | 36.83 | 37.16 | 12.05 | 22.25 | 12.97 | 4.02 |
Pretax Income | -167.73 | -201.38 | -328.96 | -356.76 | -265.27 | -235.52 |
Earnings From Continuing Operations | -167.73 | -201.38 | -328.96 | -356.76 | -265.27 | -235.52 |
Minority Interest in Earnings | - | - | - | - | 5.21 | 4.79 |
Net Income | -167.73 | -201.38 | -328.96 | -356.76 | -260.06 | -230.73 |
Net Income to Common | -167.73 | -201.38 | -328.96 | -356.76 | -260.06 | -230.73 |
Shares Outstanding (Basic) | 373 | 373 | 374 | 364 | 361 | 288 |
Shares Outstanding (Diluted) | 373 | 373 | 374 | 364 | 361 | 288 |
Shares Change (YoY) | -0.12% | -0.24% | 2.69% | 0.79% | 25.23% | 9.40% |
EPS (Basic) | -0.45 | -0.54 | -0.88 | -0.98 | -0.72 | -0.80 |
EPS (Diluted) | -0.45 | -0.54 | -0.88 | -0.98 | -0.72 | -0.80 |
Free Cash Flow | -218.11 | -191.12 | -396.52 | -429.42 | -570.22 | -356.59 |
Free Cash Flow Per Share | -0.58 | -0.51 | -1.06 | -1.18 | -1.58 | -1.24 |
Gross Margin | 27.74% | 26.14% | 28.99% | 18.16% | -22.74% | 8.85% |
Operating Margin | -192.90% | -213.87% | -301.28% | -470.32% | -793.34% | -526.88% |
Profit Margin | -118.79% | -155.54% | -287.94% | -421.01% | -642.07% | -494.89% |
Free Cash Flow Margin | -154.47% | -147.61% | -347.07% | -506.74% | -1407.84% | -764.83% |
EBITDA | -268.43 | -256.28 | -301.34 | -352.29 | -283.37 | -207.46 |
EBITDA Margin | -190.10% | -197.94% | -263.76% | - | - | - |
D&A For EBITDA | 3.94 | 20.63 | 42.88 | 46.27 | 37.96 | 38.19 |
EBIT | -272.37 | -276.9 | -344.22 | -398.56 | -321.33 | -245.65 |
EBIT Margin | -192.89% | -213.87% | - | - | - | - |
Revenue as Reported | 141.2 | 129.47 | 114.25 | 84.74 | 40.5 | 46.62 |
Advertising Expenses | - | 0.52 | 0.31 | 0.09 | 1.13 | 0.81 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.